Tryvio: Dosage Form, Projected Sales, NCE-1 Date | Aprocitentan

Tryvio

Tryvio is an oral tablet that lowers blood pressure in adults whose hypertension isn’t managed well despite using multiple medications. It blocks endothelin receptors to relax blood vessels, reducing risks of stroke and heart attack.

The information outlined in the molecule details section below would help you evaluate Para IV filing opportunities early to secure a first-to-file advantage.

Molecule Details :

Molecule Name :

Aprocitentan
Innovator :

IDORSIA PHARMACEUTICALS LTD
Approval Date :

19-Mar-24
NCE-1 Date :

19-Mar-28
NCE Date :

19-Mar-29
Dosage Form :

Tablet
Strength :

12.5mg
Therapeutic Category :

Antihypertensive
Revenue ($M) :

NA

Year-wise Projected Sales ($M) :

2025 :

17
2026 :

31
2027 :

49
2028 :

68
2029 :

83
2030 :

86
2031 :

91

Looking for this molecule for your next clinical research? Access regulatory-compliant comparators with assured timelines—delivered reliably through our global network.

Why Partner With Us

Supported 1000+ clinical trials globally
Provides services across regulatory, legal & clinical research
Unmatched intelligence on batches, expiry, spacing, and historical data from innovators
Integrated CRO services as part of our offerings
Insights on global pricing for smarter clinical trial supply decisions
Global sourcing capability across US, EU, South Africa, Canada, Japan, Australia, New Zealand, Southeast Asia, and other key markets

Tryvio

Molecule Details :

Year-wise Projected Sales ($M) :

Looking for this molecule for your next clinical research? Access regulatory-compliant comparators with assured timelines—delivered reliably through our global network.

Why Partner With Us

Login With

Are you sure want to logout from NCE Grid?